Bullement, Ash
Willis, Anna
Amin, Amerah
Schlichting, Michael
Hatswell, Anthony James
Bharmal, Murtuza http://orcid.org/0000-0001-7689-5769
Funding for this research was provided by:
Merck KGaA
Article History
Received: 3 October 2019
Accepted: 28 April 2020
First Online: 6 May 2020
Ethics approval and consent to participate
: This study contains use of data and findings from the JAVELIN Merkel 200 trial. The JAVELIN Merkel 200 trial was registered with ClinicalTrials.gov asExternalRef removedon June 4, 2014. All patients were enrolled in accordance with approved protocols, international standards of good clinical practice, institutional review board approvals, and institutional safety monitoring. Written informed consent was obtained for the use of the collected data for research. No further ethics approval was needed for analysis conducted as part of this study.
: Not applicable.
: MB is an employee of EMD Serono, Rockland, MA, USA (a business of Merck KGaA, Darmstadt, Germany); MS is an employee of Merck KGaA, Darmstadt, Germany; AA is an employee of EMD Serono, Northwood, UK. AB and AJH are employees of Delta Hat, who were a paid consultant to Merck KGaA, Darmstadt, Germany. AW is an employee of BresMed, who were a paid consultant to Merck KGaA, Darmstadt, Germany.